Strain-induced accelerated asymmetric spatial degradation of polymeric vascular scaffolds

Significance Bioresorbable scaffolds (BRS) were thought to represent the next cardiovascular interventional revolution yet they failed compared with metal stents. When BRS were tested using methods for MS, no signal of concern emerged––perhaps because BRS are not metal stents. BRS not only degrade, they also possess significant localized structural irregularities that cause asymmetric degradation. We posit these microstructural irregularities are responsible for variability in device performance in first-generation BRS. We correlated nonuniform degradation with variation in polymer microstructure and tolerance to integrated strain generated during fabrication and implantation. Differentiating failure modes in metallic and polymeric devices explains clinical results and suggests optimization strategies for the design and fabrication of next-generation BRS, indeed all devices using degradable materials. Polymer-based bioresorbable scaffolds (BRS) seek to eliminate long-term complications of metal stents. However, current BRS designs bear substantially higher incidence of clinical failures, especially thrombosis, compared with metal stents. Research strategies inherited from metal stents fail to consider polymer microstructures and dynamics––issues critical to BRS. Using Raman spectroscopy, we demonstrate microstructural heterogeneities within polymeric scaffolds arising from integrated strain during fabrication and implantation. Stress generated from crimping and inflation causes loss of structural integrity even before chemical degradation, and the induced differences in crystallinity and polymer alignment across scaffolds lead to faster degradation in scaffold cores than on the surface, which further enlarge localized deformation. We postulate that these structural irregularities and asymmetric material degradation present a response to strain and thereby clinical performance different from metal stents. Unlike metal stents which stay patent and intact until catastrophic fracture, BRS exhibit loss of structural integrity almost immediately upon crimping and expansion. Irregularities in microstructure amplify these effects and can have profound clinical implications. Therefore, polymer microstructure should be considered in earliest design stages of resorbable devices, and fabrication processes must be well-designed with microscopic perspective.

[1]  J. Mehilli,et al.  Predilation, sizing and post-dilation scoring in patients undergoing everolimus-eluting bioresorbable scaffold implantation for prediction of cardiac adverse events: development and internal validation of the PSP score. , 2017, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[2]  Patrick W Serruys,et al.  Possible mechanical causes of scaffold thrombosis: insights from case reports with intracoronary imaging. , 2017, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[3]  Bernard Chevalier,et al.  Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial , 2016, The Lancet.

[4]  M. Rayner,et al.  Cardiovascular disease in Europe: epidemiological update 2016. , 2016, European heart journal.

[5]  J. Kornfield,et al.  Multiplicity of morphologies in poly (l-lactide) bioresorbable vascular scaffolds , 2016, Proceedings of the National Academy of Sciences.

[6]  Heribert Schunkert,et al.  Everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a meta-analysis of randomised controlled trials , 2016, The Lancet.

[7]  Michael J Lipinski,et al.  Scaffold Thrombosis After Percutaneous Coronary Intervention With ABSORB Bioresorbable Vascular Scaffold: A Systematic Review and Meta-Analysis. , 2016, JACC. Cardiovascular interventions.

[8]  A C Bobel,et al.  Computational Bench Testing to Evaluate the Short-Term Mechanical Performance of a Polymeric Stent , 2015, Cardiovascular Engineering and Technology.

[9]  Patrick Segers,et al.  A finite element strategy to investigate the free expansion behaviour of a biodegradable polymeric stent. , 2015, Journal of biomechanics.

[10]  J. Tijssen,et al.  Initial experience and clinical evaluation of the Absorb bioresorbable vascular scaffold (BVS) in real-world practice: the AMC Single Centre Real World PCI Registry. , 2015, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[11]  Antonio Colombo,et al.  Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry. , 2015, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[12]  Zhaohua Chang,et al.  Degradation Model of Bioabsorbable Cardiovascular Stents , 2014, PloS one.

[13]  Varesh Prasad,et al.  Macro- and microscale variables regulate stent haemodynamics, fibrin deposition and thrombomodulin expression , 2014, Journal of The Royal Society Interface.

[14]  A. Albertsson,et al.  Tuning the Degradation Profiles of Poly(l-lactide)-Based Materials through Miscibility , 2013, Biomacromolecules.

[15]  M. Lebourg,et al.  Hydrolytic degradation of PLLA/PCL microporous membranes prepared by freeze extraction , 2012 .

[16]  E. Edelman,et al.  Stent Thrombogenicity Early in High-Risk Interventional Settings Is Driven by Stent Design and Deployment and Protected by Polymer-Drug Coatings , 2011, Circulation.

[17]  R. Rapoza,et al.  Design principles and performance of bioresorbable polymeric vascular scaffolds. , 2009, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[18]  J. Margolis,et al.  Hideo Tamai memorial , 2009 .

[19]  Simon Wandel,et al.  Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis , 2007, The Lancet.

[20]  Dong-Gu Shin,et al.  Frequency of stent fracture as a cause of coronary restenosis after sirolimus-eluting stent implantation. , 2007, The American journal of cardiology.

[21]  P. Serruys,et al.  A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. , 2007, The New England journal of medicine.

[22]  S. Pocock,et al.  Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. , 2007, The New England journal of medicine.

[23]  J. Forrester,et al.  Stent fracture associated with drug‐eluting stents: Clinical characteristics and implications , 2007, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[24]  R. Young,et al.  Molecular orientation distributions in a biaxially oriented poly(L-lactic acid) film determined by polarized Raman spectroscopy , 2006 .

[25]  Jason A Burdick,et al.  An initial investigation of photocurable three-dimensional lactic acid based scaffolds in a critical-sized cranial defect. , 2003, Biomaterials.

[26]  P. Taddei,et al.  Vibrational spectroscopy of polymeric biomaterials , 2001 .

[27]  L. Nicolais,et al.  Influence of crystal and amorphous phase morphology on hydrolytic degradation of PLLA subjected to different processing conditions , 2001 .

[28]  S. Shalaby,et al.  Change in stiffness and effect of orientation in degrading polylactide films. , 1998, Biomaterials.

[29]  W S Pietrzak,et al.  Bioabsorbable Polymer Science for the Practicing Surgeon , 1997, The Journal of craniofacial surgery.

[30]  Stephen P. McCarthy,et al.  Effects of physical aging, crystallinity, and orientation on the enzymatic degradation of poly(lactic acid) , 1996 .

[31]  M. Leon,et al.  Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study. , 1996, Circulation.

[32]  M. Vert,et al.  Vibrational analysis of poly(L‐lactic acid) , 1995 .

[33]  D. Baim,et al.  Mechanisms of restenosis and redilation within coronary stents--quantitative angiographic assessment. , 1993, Journal of the American College of Cardiology.

[34]  C. Marega,et al.  Structure and crystallization kinetics of poly(L-lactic acid) , 1992 .

[35]  Michel Vert,et al.  Structure-property relationships in the case of the degradation of massive aliphatic poly-(α-hydroxy acids) in aqueous media , 1990 .

[36]  G. Wegner,et al.  Investigation of the structure of solution grown crystals of lactide copolymers by means of chemical reactions , 1973 .

[37]  B. Tell,et al.  Raman Effect in Zinc Oxide , 1966 .

[38]  Patrick W Serruys,et al.  From metallic cages to transient bioresorbable scaffolds: change in paradigm of coronary revascularization in the upcoming decade? , 2012, European heart journal.

[39]  C. Fagnano,et al.  Vibrational Spectroscopy of Biodegradable Polymers , 1997 .

[40]  Yoshito Ikada,et al.  Properties and morphologies of poly(l-lactide): 1. Annealing condition effects on properties and morphologies of poly(l-lactide) , 1995 .

[41]  C. M. Agrawal,et al.  Evaluation of poly(L-lactic acid) as a material for intravascular polymeric stents. , 1992, Biomaterials.